Renaissance Capital logo

Vir Biotechnology Priced, Nasdaq: VIR

Phase 2 biotech developing immunologic therapies for infectious diseases.

Industry: Health Care

Latest Trade: $14.50 0.00 (0.0%)

First Day Return: -29.9%

Return from IPO: -27.5%

Industry: Health Care

We are a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Infectious diseases are one of the leading causes of death worldwide and cause hundreds of billions of dollars of economic burden each year. We believe that now is the time to apply the recent and remarkable advances in immunology to combat infectious diseases. Our approach begins with identifying the limitations of the immune system in combating a particular pathogen, the vulnerabilities of that pathogen and the reasons why previous approaches have failed. We then bring to bear powerful technologies that we believe, individually or in combination, will lead to effective therapies. We have assembled four technology platforms, focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid (siRNA), through internal development, collaborations and acquisitions. Our current development pipeline consists of product candidates targeting HBV, influenza A, HIV, and TB.
more less
IPO News for Vir Biotechnology
more
IPO Data
IPO File Date 09/03/2019
Offer Price $20.00
Price Range $20.00 - $22.00
Offer Shares (mm) 7.1
Deal Size ($mm) $143
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/10/2019
Offer Price $20.00
Price Range $20.00 - $22.00
Offer Shares (mm) 7.1
Deal Size ($mm) $143
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters San Francisco, CA
Founded 2016
Employees 206
Website www.vir.bio